President Kenyatta lauds Kenyan company, Revital Healthcare, that's exported 70M COVID-19 vaccine syringes

President Kenyatta lauds Kenyan company, Revital Healthcare, that's exported 70M COVID-19 vaccine syringes

File image of Revital Healthcare Company's staff at work. PHOTO/COURTESY

  • Revital Healthcare is an EPZ company that was launched by President Kenyatta in the Coast region to meet the global demand for auto-disable syringes production.
  • “In 2020 alone, Revital exported 70 million COVID-19 syringes to over 20 countries globally,” President Kenyatta said.


President Uhuru Kenyatta has recognised Revital Healthcare (EPZ), a Kenyan medical supply manufacturer, for being the continent’s largest producer of COVID-19 vaccines syringes.

Speaking during his eighth State of the Nation Address on Tuesday, President Kenyatta acknowledged the efforts of the Kilifi-based company in spearheading the Country’s economy in terms of innovation in the manufacturing industry.

The Head of State noted that in 2020 alone, Revital exported 70 million COVID-19 syringes to over 20 countries globally.

“A Kenyan company known as Revital operating in Kilifi County in Coast region became Africa’s largest producer and exporter of COVID-19 vaccine syringes during the COVID period,” Kenyatta stated.

The head of state further recognized the company’s role in the fight against the COVID-19 virus since its resurgence in early 2020 and the economic role it is going to play in the future.

“In fact, Revital currently has the capacity to produce 300 million Covid vaccine syringes every year. The global shortage for the COVID-19 syringes stands at 2 billion and this alone is taking advantage of opportunities,” the president noted.

He added: “This means that Revital company is able to produce one out of every ten COVID-19  vaccine syringes globally. 

Revital Healthcare is an EPZ company that was launched by President Kenyatta in the Coast region to meet the global demand for auto-disable syringes production.

The company focuses on the manufacture of Single-use syringes, Needles, Auto disable syringes, Auto disable syringes for fixed-dose immunization, Infusion Sets, Blood Transfusion Sets and Blood Collection Tubes.

Early in November 2021, the company reported having received about Ksh.400 million ($4 million) from the Bill & Melinda Gates Foundation to expand its syringe production volume from approximately 72 million to nearly 265 million annually towards the end of 2022.